

Amendments to the Claims:

Please amend the claims as follows. The following listing should replace all previous listings of the claims.

1. (Currently amended) A process for stimulating the immune system of a subject to produce and release antimalignin antibody, said process comprising administering to the subject an effective amount of a first dosage of a composition comprising malignin, recognin M, Recognin L or a peptide having the immunological specificity thereof, which process does not by itself protect against or treat cancer.
2. (Original) The process of claim 1 wherein the composition is administered as an approximately 1 mg dosage form.
3. (Original) The method of claim 1 further comprising administering a second dose of the composition ten days after administration of the first dosage.
4. (Original) The method of claim 3 further comprising administering a third dose of the composition ten days after administration of the second dosage.
5. (Currently amended) A composition for stimulating the immune system of a subject to produce and release antimalignin antibody, said composition comprising malignin, recognin M, recognin L or a peptide having the immunological specificity thereof, wherein said stimulating the immune system does not by itself protect against or treat cancer.
6. (Withdrawn) An antimalignin antibody.


7. (Withdrawn) A device for removing cancer cells from the body of a subject, said device comprising cells having immunological specificity for malignin, recognin L or recognin M, wherein said device binds, absorbs or engulfs cancer cells which come into contact therewith.
8. (Withdrawn) The device of claim 7 wherein said device comprises a filter through which the cancer cells are passed.
9. (Withdrawn) The device of claim 7 wherein the device comprises a surface over which the cancer cells are passed.
10. (Withdrawn) The device of claim 7 wherein the device comprises a resin over which the cancer cells are passed.
11. (Withdrawn) The device of claim 7 wherein the cells are selected from the group consisting of T cells, B cells and phagocytes.
12. (Withdrawn) A process for ascertaining the presence of cells transformed to the malignant state in a subject
 - (1) obtaining a fluid or tissue specimen from the subject;
 - (2) quantifying the amounts of antimalignin antibody and/or immune cells having specificity for malignin, recognin L and/or recognin M in the fluid or tissue specimen;
 - (3) correlating the amounts to the presence of cells transformed to the malignant state.

13. (Withdrawn) An antimalignin antibody having a cytotoxic agent attached thereto.

Respectfully submitted,

KENYON & KENYON

Dated: 11/18/05


Teresa A. Lavenue
Reg. No. 47,737

1500 K Street, N.W.- Suite 700
Washington, DC 20005
Telephone: 202/220-4200
Facsimile: 202/220-4201